News

Merck buys Raleigh pharma company for $10 billion, drawn by new COPD drug
Verona Pharma's flagship drug last year became the first new maintenance treatment for chronic obstructive pulmonary disease ...
Merck Acquires Verona Pharma for $10B to Support Portfolio with COPD Drug Ohtuvayre Ahead of Keytruda Patent Expiration
Merck & Co. Inc. (NYSE:MRK) is one of the most undervalued NYSE stocks to buy now. On July 9, Merck announced its acquisition ...
GEN - Genetic Engineering and Biotechnology News14h
Merck to Acquire Verona Pharma for $10B, Adding Fast-Growing COPD Drug
Merck & Co. has agreed to acquire Verona Pharma for $10 billion, the companies said, in a deal designed to expand the pharma ...
Merck: FDA to Review Doravirine/Islatravir Regimen in HIV-1 Infection
Merck on Thursday said the application covers the investigational, once-daily, oral two-drug regimen for adults with HIV-1 infection that is virologically suppressed on antiretroviral therapy. The ...
Merck & Co.: A Pharma Titan At A Discount
Merck is a massive company with strong fundamentals and underlying value at a heavily discounted price. Click here to find ...
Merck to Buy Verona for $10 Billion as Patent Cliff Looms
Merck & Co. agreed to buy respiratory drugmaker Verona Pharma Plc for around $10 billion as part of its ongoing search for ways to fill the Keytruda-sized hole that will emerge over the next few years ...
Barchart on MSN1d
What You Need To Know Ahead of Merck's Earnings Release
Merck is set to announce its second-quarter results later this month, and analysts anticipate double-digit earnings dip.
Fierce Pharma5h
Pressuring Merck's Gardasil, China's home-made 9-valent HPV vaccine priced at 60% discount
China’s first domestically made nine-valent HPV vaccine, a direct competitor to Merck’s Gardasil 9, is being priced at 499 ...
UBS Affirms Merck & Co’s (MRK) ‘Buy’ Rating on HPV Vaccine Prospects
Merck & Co., Inc. (NYSE:MRK) is one of the 10 best defensive stocks to buy in a volatile market. On July 2, UBS reiterated a ...